Terms search
1
Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery, and Therapy
Ioannis S. Vizirianakis (Editor)
2
Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery, and Therapy
Ioannis S Vizirianakis
3
Handbook of Pharmacogenomics and Stratified Medicine
Sandosh Padmanabhan (ed.)
4
Pharmacogenics - Challenges and Opportunities in Therapeutic Implementation
Y. W. Francis Lam; Stuart A. Scott
5
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou; Shu-Feng; Liu; Jun-Ping; Chowbay; Balram
6
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic; Slobodan
8
Cytochrome P450 2D6
Shufeng Zhou
9
Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction
Kiss; Ádám Ferenc; Vaskó; Dorottya; Déri; Máté Tamás; Tóth; Katalin; Monostory; Katalin
10
Pharmacogenomics in Admixed Populations
Guilherme Suarez-kurtz
11
Distribution of CYP2C19*17 allele and genotypes in an Indian population
D. Anichavezhi; U. S. Chakradhara Rao; D. G. Shewade; R. Krishnamoorthy; C. Adithan
12
Pharmacogenomics in Clinical Therapeutics
Loralie J. Langman; Amitava Dasgupta
13
Applying Pharmacogenomics in Therapeutics
Feng; Xiaodong; Xie; Hong-Guang
14
Update on the pharmacogenomics of proton pump inhibitors
Hagymási; Krisztina; Müllner; Katalin; Herszényi; László; Tulassay; Zsolt
15
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SIM; S; RISINGER; C; DAHL; M; AKLILLU; E; CHRISTENSEN; M; BERTILSSON; L; INGELMANSUNDBERG; M
16
Drug-Drug Interactions
A. David Rodrigues
17
Drug - Drug Interactions (Drugs and the Pharmaceutical Sciences)
A. David Rodrigues
18
Drug - Drug Interactions (Drugs and the Pharmaceutical Sciences)
A. David Rodrigues
19
Drug - Drug Interactions (Drugs and the Pharmaceutical Sciences)
A. David Rodrigues
20
Drug - Drug Interactions (Drugs and the Pharmaceutical Sciences)
A. David Rodrigues
21
Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with differentCYP2C19genotypes
Li-Jun Yang; Lan Fan; Zhao-Qian Liu; Yan-Mei Mao; Dong Guo; Li-Hui Liu; Zhi-Rong Tan; Liang Peng; Chun-Ting Han; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
22
Concepts in Pharmacogenomics
Martin M. Zdanowicz
23
Drug-Drug Interactions
Rodrigues; David
24
Drug-Drug Interactions, Second Edition (Drugs and the Pharmaceutical Sciences)
A. David Rodrigues
25
Drug-Drug Interactions
Rodrigues A. D. (ed.)
26
Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood
Ersin Gumus; Ozgur Karaca; Melih O. Babaoglu; Gökhan Baysoy; Necati Balamtekin; Hulya Demir; Nuray Uslu; Atilla Bozkurt; Aysel Yuce; Umit Yasar
27
Metabolism of Drugs and Other Xenobiotics
Pavel Anzenbacher & Ulrich M. Zanger [Anzenbacher; Pavel & Zanger; Ulrich M.]
28
Metabolism of Drugs and Other Xenobiotics
Pavel Anzenbacher; Ulrich M. Zanger
29
Genetics of Cardiovascular Disease
Timothy J.A. Chico (Eds.)
30
Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond
Hong-Guang Xie; Jian-Jun Zou; Zuo-Ying Hu; Jun-Jie Zhang; Fei Ye; Shao-Liang Chen
31
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
32
Pharmacogenomics of clopidogrel: Evidence and perspectives
Tong Yin; Toshiyuki Miyata
33
Serum concentrations of sertraline and N-desmethyl sertraline in relation toCYP2C19genotype in psychiatric patients
I. Rudberg; M. Hermann; H. Refsum; E. Molden
34
Characterization of CYP2C19 and CYP2C9 from Human Liver: Respective Roles in Microsomal Tolbutamide,S-Mephenytoin, and Omeprazole Hydroxylations
Jerome M. Lasker; Michael R. Wester; Eileen Aramsombatdee; Judy L. Raucy
35
Pharmacogenetics and Individualized Therapy
Anke-Hilse Maitland-van der Zee; Ann K. Daly
36
Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response
Sunishtha S. Yadav; Munindra Ruwali; Parag P. Shah; Neeraj Mathur; Ram L. Singh; Mohan C. Pant; Devendra Parmar
37
Economic Dimensions of Personalized and Precision Medicine
Ernst R. Berndt (editor); Dana P. Goldman (editor); John Rowe (editor)
38
Economic Dimensions of Personalized and Precision Medicine (National Bureau of Economic Research Conference Report)
Ernst R. Berndt (editor); Dana P. Goldman (editor); John Rowe (editor)
39
CYP2C19 genetic mutations in North Indians
Lamba; J
40
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations
Ellis; Kyle J; Stouffer; George A; McLeod; Howard L; Lee; Craig R
41
Genetic polymorphism analysis of
CYP2C19
in Chinese Han populations from different geographic areas of mainland China
Chen; Lingling; Qin; Shengying; Xie; Jing; Tang; Jimin; Yang; Lun; Shen; Wen; Zhao; Xinzhi; Du; Jing; He; Guang; Feng; Guoyin; He; Lin; Xing; Qinghe
42
Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients
Rudberg; I; Mohebi; B; Hermann; M; Refsum; H; Molden; E
43
INHIBITION OF ADP-INDUCED PLATELET AGGREGATION BY CLOPIDOGREL IS RELATED TO CYP2C19 GENETIC POLYMORPHISMS
Bi-Lian Chen; Wei Zhang; Qing Li; Ya-Lin Li; Yi-Jing He; Lan Fan; Lian-Sheng Wang; Zhao-Qian Liu; Hong-Hao Zhou
